# Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

> **NCT02551159** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 823 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **BIOLOGICAL:** MEDI4736
- **BIOLOGICAL:** Tremelimumab
- **BIOLOGICAL:** MEDI4736+Tremelimumab
- **BIOLOGICAL:** Cetuximab
- **DRUG:** 5-fluorouracil (5FU)
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02551159
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-15
- **Primary completion:** 2020-07-06
- **Final completion:** 2021-05-21
- **Target enrollment:** 823 (ACTUAL)
- **Last updated:** 2021-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02551159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02551159, "Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02551159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*